NCT03576963View on ClinicalTrials.gov

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 30, 2020

Primary Completion Date

January 30, 2022

Study Completion Date

January 30, 2023

Conditions
Colorectal AdenocarcinomaCpG Island Methylator PhenotypeMetastatic Microsatellite Stable Colorectal CarcinomaRefractory Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8
Interventions
DRUG

Guadecitabine

Given SC

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (2)

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

92658

Hoag Memorial Hospital Presbyterian, Newport Beach

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

University of Southern California

OTHER